Cargando…

Digital Quantification of Tumor PD-L1 Predicts Outcome of PD-1-Based Immune Checkpoint Therapy in Metastatic Melanoma

BACKGROUND: PD-1-based immune checkpoint blockade (ICB) is a highly effective therapy in metastatic melanoma. However, 40-60% of patients are primarily resistant, with valid predictive biomarkers currently missing. This study investigated the digitally quantified tumor PD-L1 expression for ICB thera...

Descripción completa

Detalles Bibliográficos
Autores principales:	Placke, Jan-Malte, Soun, Camille, Bottek, Jenny, Herbst, Rudolf, Terheyden, Patrick, Utikal, Jochen, Pföhler, Claudia, Ulrich, Jens, Kreuter, Alexander, Pfeiffer, Christiane, Mohr, Peter, Gutzmer, Ralf, Meier, Friedegund, Dippel, Edgar, Weichenthal, Michael, Zimmer, Lisa, Livingstone, Elisabeth, Becker, Jürgen C., Lodde, Georg, Sucker, Antje, Griewank, Klaus, Horn, Susanne, Hadaschik, Eva, Roesch, Alexander, Schadendorf, Dirk, Engel, Daniel Robert, Ugurel, Selma
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8491983/ https://www.ncbi.nlm.nih.gov/pubmed/34621681 http://dx.doi.org/10.3389/fonc.2021.741993

Ejemplares similares

Correlation of tumor PD-L1 expression in different tissue types and outcome of PD-1-based immunotherapy in metastatic melanoma – analysis of the DeCOG prospective multicenter cohort study ADOREG/TRIM
por: Placke, Jan-Malte, et al.
Publicado: (2023)

Apoptotic Gastritis in Melanoma Patients Treated With PD-1-Based Immune Checkpoint Inhibition – Clinical and Histopathological Findings Including the Diagnostic Value of Anti-Caspase-3 Immunohistochemistry
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations
por: Cosgarea, Ioana, et al.
Publicado: (2017)

Effectiveness, Safety and Utilization of Vismodegib for Locally Advanced Basal Cell Carcinoma Under Real-world Conditions: Non-interventional Cohort Study JONAS
por: KAATZ, Martin, et al.
Publicado: (2022)

Genetic and Clinical Characteristics of ARID1A Mutated Melanoma Reveal High Tumor Mutational Load without Implications on Patient Survival
por: Thielmann, Carl Maximilian, et al.
Publicado: (2022)

Impact of a preceding radiotherapy on the outcome of immune checkpoint inhibition in metastatic melanoma: a multicenter retrospective cohort study of the DeCOG
por: Knispel, Sarah, et al.
Publicado: (2020)

Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma
por: Spassova, Ivelina, et al.
Publicado: (2022)

Impact of radiotherapy and sequencing of systemic therapy on survival outcomes in melanoma patients with previously untreated brain metastasis: a multicenter DeCOG study on 450 patients from the prospective skin cancer registry ADOREG
por: Franklin, Cindy, et al.
Publicado: (2022)

Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
por: Váraljai, Renáta, et al.
Publicado: (2023)

Author Correction: Interleukin 17 signaling supports clinical benefit of dual CTLA-4 and PD-1 checkpoint inhibition in melanoma
por: Váraljai, Renáta, et al.
Publicado: (2023)

Discontinuation of BRAF/MEK-Directed Targeted Therapy after Complete Remission of Metastatic Melanoma—A Retrospective Multicenter ADOReg Study
por: Stege, Henner, et al.
Publicado: (2021)

COVID-19 vaccination in advanced skin cancer patients receiving systemic anticancer treatment: A prospective singlecenter study investigating seroconversion rates
por: Lodde, Georg C., et al.
Publicado: (2022)

Circulating cell‐free messenger RNA enables non‐invasive pan‐tumour monitoring of melanoma therapy independent of the mutational genotype
por: Albrecht, Lea Jessica, et al.
Publicado: (2022)

Real-World Therapy with Pembrolizumab: Outcomes and Surrogate Endpoints for Predicting Survival in Advanced Melanoma Patients in Germany
por: Mohr, Peter, et al.
Publicado: (2022)

Durable Complete Response in a Melanoma Patient With Unknown Primary, Associated With Sequential and Severe Multi-Organ Toxicity After a Single Dose of CTLA-4 Plus PD-1 Blockade: A Case Report
por: Matull, Johanna, et al.
Publicado: (2020)

Brain metastasis and survival outcomes after first-line therapy in metastatic melanoma: a multicenter DeCOG study on 1704 patients from the prospective skin cancer registry ADOREG
por: Franklin, Cindy, et al.
Publicado: (2023)

Medical Needs and Therapeutic Options for Melanoma Patients Resistant to Anti-PD-1-Directed Immune Checkpoint Inhibition
por: Hassel, Jessica C., et al.
Publicado: (2023)

Serologic and immunohistochemical prognostic biomarkers of cutaneous malignancies
por: Utikal, Jochen, et al.
Publicado: (2007)

Kutanes Angiosarkom mit klinischem Bild eines Quincke-Ödems
por: Albrecht, M., et al.
Publicado: (2021)

Coronavirus disease 2019 vaccine mimics lymph node metastases in patients undergoing skin cancer follow-up: A monocentre study
por: Placke, Jan-Malte, et al.
Publicado: (2021)

Factors Influencing the Adjuvant Therapy Decision: Results of a Real-World Multicenter Data Analysis of 904 Melanoma Patients
por: Lodde, Georg, et al.
Publicado: (2021)

Early Exanthema Upon Vemurafenib Plus Cobimetinib Is Associated With a Favorable Treatment Outcome in Metastatic Melanoma: A Retrospective Multicenter DeCOG Study
por: Kähler, Katharina C., et al.
Publicado: (2021)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Re-Induction following Resistance or Toxicity
por: Koch, Elias A. T., et al.
Publicado: (2022)

Immune Checkpoint Blockade for Metastatic Uveal Melanoma: Patterns of Response and Survival According to the Presence of Hepatic and Extrahepatic Metastasis
por: Koch, Elias A. T., et al.
Publicado: (2021)

Treatment management for BRAF-mutant melanoma patients with tumor recurrence on adjuvant therapy: a multicenter study from the prospective skin cancer registry ADOREG
por: Haist, Maximilian, et al.
Publicado: (2023)

SARS-CoV-2 infections in melanoma patients treated with PD-1 inhibitors: A survey of the German ADOREG melanoma registry
por: Moritz, Rose K.C., et al.
Publicado: (2021)

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?
por: Zaremba, Anne, et al.
Publicado: (2019)

COVID-19 vaccination in psoriasis patients receiving systemic treatment: A prospective single-center study
por: Lodde, Georg Christian, et al.
Publicado: (2023)

Genetic and Methylation Analysis of CTNNB1 in Benign and Malignant Melanocytic Lesions
por: Zaremba, Anne, et al.
Publicado: (2022)

Clinical determinants of long-term survival in metastatic uveal melanoma
por: Koch, Elias A. T., et al.
Publicado: (2021)

STAT3 Single Nucleotide Polymorphism rs4796793 SNP Does Not Correlate with Response to Adjuvant IFNα Therapy in Stage III Melanoma Patients
por: Schrama, David, et al.
Publicado: (2014)

Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
por: Zimmer, Lisa, et al.
Publicado: (2015)

Lack of SF3B1 R625 mutations in cutaneous melanoma
por: Schilling, Bastian, et al.
Publicado: (2013)

Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
por: Liu, David, et al.
Publicado: (2019)

GNA14, GNA11, and GNAQ Mutations Are Frequent in Benign but Not Malignant Cutaneous Vascular Tumors
por: Jansen, Philipp, et al.
Publicado: (2021)

Medikamentöse Therapie des inoperablen Melanoms
por: Lodde, Georg, et al.
Publicado: (2023)

Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade
por: Bochem, Jonas, et al.
Publicado: (2019)

Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
por: Liu, David, et al.
Publicado: (2020)

Response to First-Line Treatment with Immune-Checkpoint Inhibitors in Patients with Advanced Cutaneous Squamous Cell Carcinoma: A Multicenter, Retrospective Analysis from the German ADOReg Registry
por: Haist, Maximilian, et al.
Publicado: (2022)

Dose-dependent severe cutaneous reactions to imatinib
por: Ugurel, S, et al.
Publicado: (2003)

Cannot write session to /tmp/vufind_sessions/sess_abeadnkk4erb176i4q5fjj09sg